Skip to content
The People's CodeSearch
Menu

Changes to the Code

H.R. 6509 · SAFE Drugs Act of 2025 ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

21 U.S.C. § 353a Pharmacy compounding

+37 −11Shown
More for 21 U.S.C. § 353a
Read § 353aOnly this section
4 changes the bill asks for here, 4 carried out
  1. Carried out:

    by amending paragraph (1)(D) to read as follows:(D) does not, more than 20 times in a single month, compound any drug product that is essentially a copy of a commercially available drug product.; and

  2. Carried out:

    by amending paragraph (2) to read as follows:(2) Definitions.— (A) For purposes of paragraph (1)(D), the term “essentially a copy of a commercially available drug product” means any drug product— (i) that contains any active ingredient found in a commercially available drug product; and (ii) in which there is no change, …

  3. Carried out:

    by redesignating subsections (d) and (e) as subsections (e) and (f), respectively; and

  4. Carried out:

    by inserting after subsection (c) the following:(d) Reporting requirement.— (1) In general.— For calendar year 2025 and each calendar year thereafter, if a pharmacy, facility, or physician compounds, more than 20 times in a single month for patients who reside outside the State in which the compounding occurs, any drug …

§ 353a(b)Compounded drug(1)–(3)

Start of § 353a to (b)(1)(B) unchanged ·

(C) does not compound a drug product that appears on a list published by the Secretary in the Federal Register of drug products that have been withdrawn or removed from the market because such drug products or components of such drug products have been found to be unsafe or not effective; and

(D) does not[inserted: ,] [struck: compound][inserted: more] [struck: regularly][inserted: than] [struck: or][inserted: 20] [inserted: times ]in [struck: inordinate][inserted: a] [struck: amounts][inserted: single] [struck: (as][inserted: month,] [struck: defined][inserted: compound] [struck: by the Secretary) ]any drug [struck: products][inserted: product] that [struck: are][inserted: is] essentially [struck: copies][inserted: a] [inserted: copy ]of a commercially available drug product.

(2) [struck: Definition][inserted: Definitions.—]

(A) [inserted: For purposes of paragraph (1)(D), the term “essentially a copy of a commercially available drug product” means any drug product—]

(i) [inserted: that contains any active ingredient found in a commercially available drug product; and]

(ii) [inserted: in which there is no change, made for an identified individual patient, which produces for that patient a significant difference, as determined by the prescribing practitioner, between the compounded drug product and the comparable commercially available drug product.]

(B) [inserted: For purposes of subparagraph (A), the term “commercially available drug product” includes any drug product that—]

(i) [inserted: is sold in the commercial marketplace in the United States and manufactured in one or more facilities required to comply with section 501(a)(2)(B); and]

(ii) [inserted: is not included in the discontinued section of the list of products described in section 505(j)(7)(A).]

[struck: For purposes of paragraph (1)(D), the term “essentially a copy of a commercially available drug product” does not include a drug product in which there is a change, made for an identified individual patient, which produces for that patient a significant difference, as determined by the prescribing practitioner, between the compounded drug and the comparable commercially available drug product.]

(3) Drug product A drug product may be compounded under subsection (a) only if—

(A) such drug product is not a drug product identified by the Secretary by regulation as a drug product that presents demonstrable difficulties for compounding that reasonably demonstrate an adverse effect on the safety or effectiveness of that drug product; and

§ 353a(c)–(f)

(b)(3)(B)–(c) unchanged ·

(1) In general The Secretary shall issue regulations to implement this section. Before issuing regulations to implement subsections (b)(1)(A)(i)(III), (b)(1)(C), or (b)(3)(A), the Secretary shall convene and consult an advisory committee on compounding unless the Secretary determines that the issuance of such regulations before consultation is necessary to protect the public health. The advisory committee shall include representatives from the National Association of Boards of Pharmacy, the United States Pharmacopoeia, pharmacy, physician, and consumer organizations, and other experts selected by the Secretary.

(2) Limiting compounding The Secretary, in consultation with the United States Pharmacopoeia Convention, Incorporated, shall promulgate regulations identifying drug substances that may be used in compounding under subsection (b)(1)(A)(i)(III) for which a monograph does not exist or which are not components of drug products approved by the Secretary. The Secretary shall include in the regulation the criteria for such substances, which shall include historical use, reports in peer reviewed medical literature, or other criteria the Secretary may identify.

(d) [inserted: Reporting requirement.—]

(1) [inserted: In general.—] [inserted: For calendar year 2025 and each calendar year thereafter, if a pharmacy, facility, or physician compounds, more than 20 times in a single month for patients who reside outside the State in which the compounding occurs, any drug product that contains any active ingredient found in a commercially available drug product (as defined in subsection (b)(2)(B)), such pharmacy, facility, or physician shall submit a report to the Secretary.]

(2) [inserted: Contents.—] [inserted: Each report under paragraph (1) shall identify—]

(A) [inserted: each type of drug product described in paragraph (1) that is compounded for a patient described in such paragraph; and]

(B) [inserted: for each month, the total number of times each such type is so compounded.]

(3) [inserted: Timing.—] [inserted: For any calendar year for which paragraph (1) applies, the pharmacy, facility, or physician shall submit the report under such paragraph not later than the end of such calendar year.]

(4) [inserted: Form and manner.—] [inserted: A pharmacy, facility, or physician shall submit each report under paragraph (1) in such form and manner as the Secretary may prescribe.]

(5) [inserted: Hospital pharmacy exclusion.—] [inserted: This subsection does not apply to the compounding of any drug products for hospital patients by a pharmacy located on the premises of the hospital.]

[struck: (d)] [inserted: (e)] Application This section shall not apply to—

(1) compounded positron emission tomography drugs as defined in section 321(ii) of this title; or

(2) radiopharmaceuticals.

[struck: (e)] [inserted: (f)] “Compounding” defined As used in this section, the term “compounding” does not include mixing, reconstituting, or other such acts that are performed in accordance with directions contained in approved labeling provided by the product’s manufacturer and other manufacturer directions consistent with that labeling.

21 U.S.C. § 353b Outsourcing facilities

+9 −0Shown
More for 21 U.S.C. § 353b
Read § 353bOnly this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 503B(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353b(b)) is amended by adding at the end the following:(6) Inspections of large-scale outsourcing facilities.— (A) In general.— In the case of a large-scale outsourcing facility, the risk-based inspections under paragraph (4) shall include— (i) an inspection prior to such facility compounding any drug product for the first time; and …

§ 353b(b)–(c)

Start of § 353b to (b)(4)(C)(v) unchanged ·

(vi) Any other criteria deemed necessary and appropriate by the Secretary for purposes of allocating inspection resources.

(5) Adverse event reporting Outsourcing facilities shall submit adverse event reports to the Secretary in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations).

(6) [inserted: Inspections of large-scale outsourcing facilities.—]

(A) [inserted: In general.—] [inserted: In the case of a large-scale outsourcing facility, the risk-based inspections under paragraph (4) shall include—]

(i) [inserted: an inspection prior to such facility compounding any drug product for the first time; and]

(ii) [inserted: the reinspection of such facility not less than biennially.]

(B) [inserted: Large-scale outsourcing facility defined.—] [inserted: For purposes of this paragraph, the term “large-scale outsourcing facility” means any outsourcing facility that compounds, more than 100 times in a single calendar year, any drug product.]

(c) Regulations

(1) In general The Secretary shall implement the list described in subsection (a)(6) through regulations.

Rest of § 353b unchanged ·

21 U.S.C. § 360 Registration of producers of drugs or devices

+1 −1Shown
More for 21 U.S.C. § 360
Read § 360Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 510(g)(1) of such Act (21 U.S.C. 360(g)(1)) is amended by inserting before the semicolon at the end the following: , except that the exemption in this paragraph shall not apply to any outsourcing facility (as defined in section 503B(d)(4)).

§ 360(g)Exclusions from application of section(1)–(3)

Start of § 360 to (f) unchanged ·

(g) Exclusions from application of section The foregoing subsections of this section shall not apply to—

(1) pharmacies which maintain establishments in conformance with any applicable local laws regulating the practice of pharmacy and medicine and which are regularly engaged in dispensing prescription drugs or devices, upon prescriptions of practitioners licensed to administer such drugs or devices to patients under the care of such practitioners in the course of their professional practice, and which do not manufacture, prepare, propagate, compound, or process drugs or devices for sale other than in the regular course of their business of dispensing or selling drugs or devices at retail[inserted: , except that the exemption in this paragraph shall not apply to any outsourcing facility (as defined in section 503B(d)(4))];

(2) practitioners licensed by law to prescribe or administer drugs or devices and who manufacture, prepare, propagate, compound, or process drugs or devices solely for use in the course of their professional practice;

(3) persons who manufacture, prepare, propagate, compound, or process drugs or devices solely for use in research, teaching, or chemical analysis and not for sale;

Rest of § 360 unchanged ·

21 U.S.C. § 379j–62 Authority to assess and use outsourcing facility fees

+1 −1Shown
More for 21 U.S.C. § 379j–62
Read § 379j–62Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 744K(c)(1)(A)(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j–62(c)(1)(A)(i)) is amended by striking $15,000 and inserting a base amount deemed appropriate by the Secretary to fund activities to ensure the safety of compounded drug products.

§ 379j–62(c)(1)In general(A)–(B)

Start of § 379j–62 to (c)(1) unchanged ·

(A) except as provided in paragraph (4), the amount of the annual establishment fee under subsection (b) shall be equal to the sum of—

(i) [struck: $15][inserted: a base amount deemed appropriate by the Secretary to fund activities to ensure the safety of compounded drug products],[struck: 000,] multiplied by the inflation adjustment factor described in paragraph (2); plus

(ii) the small business adjustment factor described in paragraph (3); and

(B) the amount of any reinspection fee (if applicable) under subsection (b) shall be equal to $15,000, multiplied by the inflation adjustment factor described in paragraph (2).

Rest of § 379j–62 unchanged ·

Step through the changes